Amylyx Pharmaceuticals, Inc. (AMLX) News
Track canonical SquawkNews coverage tagged to AMLX, Amylyx Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
AMLX: Guggenheim Raises Target
Guggenheim analyst Seamus Fernandez maintains Buy on Amylyx Pharmaceuticals and raises the price target to $40
EQUITY | Jun 25, 2026, 02:12 PM UTC
M
AMLX Presents ALS Trial Data
Amylyx Pharmaceuticals presents data from first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 in ALS at ENCALS 2026
EQUITY | Jun 23, 2026, 11:00 AM UTC